Aviado · Research
Longevity Daily
Saturday, August 29, 2026
Listen
Today's Brief
Timing is everything in longevity medicine — and today's digest proves it on multiple fronts. Our lead story reframes hormone therapy as a potential brain-protective drug, but only for women who start early; waiting until after menopause may reverse the benefit entirely. A world-first Australian trial delivers the clearest evidence yet that statins cut cardiovascular risk by 30% in healthy adults over 70, and a landmark mouse study in Aging Cell shows that clearing senescent cells after cancer treatment extends survival — but only when the intervention is timed correctly. Rounding out a strong issue: MIT Technology Review scrutinizes a startup claiming its drug combo can make blood "young," and Pharmacy Times takes a hard look at Neuriva's evidence gap.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
HRT May Cut Dementia Risk — But Only If You Start It Early Enough
For decades, hormone replacement therapy carried a stigma around brain health, but a large and growing body of research is flipping that narrative. A new analysis cited by Business Insider finds that estrogen started early in menopause appears to protect and sustain brain health, while starting it after menopause may actually increase risk — a distinction that changes the clinical calculus entirely. "Early intervention promotes and sustains brain health, and postmenopausal intervention does not," says neuroscientist Roberta Brinton, director of the Center for Innovation in Brain Science at the University of Arizona. If you're approaching or in early menopause, this is a conversation worth having with your doctor now — the window of opportunity appears to be real and time-limited.
Read more →1 in 4 Former NFL Players Had CTE at Death, New Data Shows
A review of former NFL player deaths from 2016–2021 found approximately 25% had chronic traumatic encephalopathy (CTE), with neurodegenerative disease listed as a primary or secondary cause of death in over 40% of those with clinician-diagnosed dementia. The findings reinforce how repeated head trauma accumulates silently over a career, with consequences that emerge decades later. For anyone who played contact sports — or has a loved one who did — this is a reminder that neurological risk doesn't end when the helmet comes off.
Read more →Supplements & Compounds
Scientists Finally Figured Out How Metformin Actually Works
After more than 60 years of widespread use, researchers have identified metformin's primary mechanism: it sharply reduces circulating levels of citrulline, a metabolite tied to metabolic signaling, in ways that likely explain the drug's glucose-lowering effects. The discovery came from directly comparing blood metabolite profiles in people taking metformin versus those unexposed to the drug. For the millions using metformin off-label for longevity — or watching the TAME trial — this mechanistic clarity may accelerate the development of better-targeted next-generation drugs.
Read more →Neuriva Is One of America's Most Popular Brain Supplements — Its Evidence Is Not
Pharmacy Times takes a rigorous look at Neuriva, the best-selling brain supplement endorsed by actress and neuroscientist Mayim Bialik, finding that its claims across five cognitive domains — memory, accuracy, learning, focus, and concentration — have not been evaluated by the FDA. The product comes in multiple formulations and is widely available in retail stores, but the gap between marketing claims and clinical evidence is significant. If you're spending money on a cognitive supplement, this is a useful reality check on what "supports brain health" actually means on a label.
Read more →Research & Papers
World-First Trial: Statins Cut Heart Attack and Stroke Risk by 30% in Healthy Over-70s
Australian researchers ran the first randomized clinical trial specifically designed to test statin therapy in healthy adults over 70 who had no prior cardiovascular disease — a population historically excluded from statin research. The result: a 30% reduction in first major cardiovascular events, with a low rate of serious side effects. This directly challenges the long-held clinical hesitation to prescribe statins to older adults who haven't yet had a cardiac event, and the data now supports the conversation.
Read more →Clearing Zombie Cells After Cancer Treatment Reverses Accelerated Aging — But Timing Is Everything
A mouse study published in Aging Cell found that selectively eliminating p16-positive senescent cells ("zombie cells") after whole-body radiation dramatically reduced frailty, improved cognitive function, restored blood-brain barrier integrity, improved liver metabolism, and extended median survival — but only when clearance was performed 4 months post-irradiation, not 1 month. Early clearance had no measurable benefit at all, suggesting the senescent cell burden needs time to accumulate before it becomes a meaningful target. For cancer survivors experiencing accelerated aging, the findings have direct implications for when senolytics might actually help — and clinical timing may matter as much as the drug itself. Note: mouse model; human translation will require dedicated trials.
Read more →Aviado Research: A Deep-Dive Analysis on Longevity Science
Aviado Research publishes an in-depth analysis synthesizing primary evidence across the longevity landscape. Aviado's work is designed to cut through the noise and help readers understand what the science actually supports — and where the gaps remain. Read the full analysis for a thorough, evidence-based perspective on this cycle's key findings.
Read the full Aviado analysis →Lifestyle & Nutrition
Chronic Traffic Noise Is Linked to Higher Parkinson's Disease Risk
Adults aged 40 and older who are chronically exposed to high levels of road traffic noise face a significantly elevated risk of developing Parkinson's disease, according to new research. The proposed mechanisms involve noise-induced chronic stress, sleep disruption, and neuroinflammation — all established contributors to neurodegeneration. For urban residents, this adds a neurological dimension to the case for noise-reduction strategies: quieter neighborhoods, sound-proofing, and sleep environment improvements may have more brain-health value than previously appreciated.
Read more →Industry & Policy
A Startup Says Its Drug Combo Can Make Your Blood Young — MIT Tech Review Is Skeptical
Generation Lab claims its proprietary drug combination can "stop the spread of aging" throughout the body — and is looking for influencers to serve as early test subjects. MIT Technology Review examines the claims critically, highlighting the significant distance between early data and the company's marketing pitch. It's a useful read for anyone tracking longevity biotech: a template for how to evaluate bold startup claims before the peer-reviewed evidence catches up.
Read more →Testosterone Interest Is Surging Across All Age Groups — and the Supplement Industry Is Taking Notice
A Nutritional Outlook panel discussion finds that consumer interest in testosterone is resurging — not just among older men, but across genders and age groups — even as joint health supplements have underperformed category growth expectations. The panel also unpacks what "healthy aging" actually means to today's supplement buyer. For longevity industry watchers, it's a useful window into where consumer attention and market dollars are flowing next.
Read more →